US Pharma MarketingA discarded Amgen T cell engager comes back to life at its California creator, 92Bio
92Bio doses the first patient in a Phase 1 trial with NTB-928, a T cell engager it reclaimed from Amgen after the company shelved the program. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and…
A small California startup is reviving an experimental T cell engager that its scientists originally developed but had handed off to Amgen years ago. After repeatedly saying it would bring the drug candidate into human ...
Source: Endpoints News